Answers are grounded in this paper and cite their sources.
Novel monoclonal antibody detects TOX1 in CD8+ T lymphocytes, suggesting its role in granzyme B and CX3CR1 expression.
Description Thymocyte selection-associated high mobility group box (TOX) transcription factors are highly expressed in the thymus. In humans, TOX1 expression is induced by intense or chronic exposure of the T cell receptor (TCR) to antigen. Recent studies have linked TOX1 expression to the exhausted phenotype of CD8+ T cells observed during chronic infection and tumor development. TOX1 has also been identified as a regulator for the survival of exhausted CD8+ T cells. In this study, we introduce a novel monoclonal antibody that detects mouse and human TOX1 by intracellular flowcytometry, Western blot and immunocytochemistry. The specificity of the TOX1 antibody was confirmed using a TOX subfamily (TOX1-4) loss of function model. TOX1 was detected by intracellular flow cytometric analysis of a T lymphoblast cell line and human CD8+ naïve and memory T cells. We found increased expression of TOX1 along with increased expression of several inhibitory receptors (including PD1, LAG3 & CD39), cytolytic proteins (including granzyme B and perforin), transcription factors Eomes and T-bet and the chemokine receptor CX3CR1. We also observed that in vitro exhaustion of CD8+ T lymphocytes promote cell death in memory T cells in contrast to naive T cells. In summary, our study demonstrates the specificity of our TOX1 antibody in multiple applications and establishes TOX1 as a potential regulator and phenotypic marker for exhausted cells that promote cell death after chronic TCR stimulation.
No takes yet. Share an insight, caveat, or question.
Jaiswal et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: